Literature DB >> 10398479

Clinical uses of cidofovir.

.   

Abstract

Cidofovir is a cytidine nucleotide analogue recently licensed as an intravenous treatment for CMV retinitis in AIDS patients. Three controlled clinical trials have demonstrated efficacy of cidofovir for this indication, and have generated data useful as a guideline to prevent potential toxicity. Although de novo emergence of resistance to cidofovir has not been observed clinically in patients receiving cidofovir, cross-resistance to cidofovir in ganciclovir-resistant clinical DNA polymerase mutants has been identified. Cross-resistance of cidofovir and foscarnet has not been identified to date. A broad spectrum agent with in vitro activity against human herpesviruses, adenovirus, HPV, polyomaviruses and human poxviruses, cidofovir is under clinical investigation for a variety of potential applications. Examples include intravenous administration of cidofovir for treatment of progressive multifocal leukoencephalopathy and Kaposi's sarcoma, intraocular injection for treatment of CMV retinitis, intralesional injection for treatment of respiratory papillomatosis, topical application for treatment of molluscum contagiosum, anogenital condyloma acuminata, and recurrent genital herpes, and ophthalmic instillation for treatment of viral keratoconjunctivitis. Copyright 1997 John Wiley & Sons, Ltd.

Entities:  

Year:  1997        PMID: 10398479     DOI: 10.1002/(sici)1099-1654(199709)7:3<145::aid-rmv196>3.0.co;2-0

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  45 in total

1.  Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies.

Authors:  Debra C Quenelle; Bernhardt Lampert; Deborah J Collins; Terri L Rice; George R Painter; Earl R Kern
Journal:  J Infect Dis       Date:  2010-10-05       Impact factor: 5.226

Review 2.  BK polyomavirus: emerging pathogen.

Authors:  Shauna M Bennett; Nicole M Broekema; Michael J Imperiale
Journal:  Microbes Infect       Date:  2012-02-24       Impact factor: 2.700

Review 3.  The search for new therapies for human cytomegalovirus infections.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Virus Res       Date:  2010-11-21       Impact factor: 3.303

4.  Acute meningoencephalitis caused by adenovirus serotype 26.

Authors:  Erik R Dubberke; Benjamin Tu; Dennis J Rivet; Gregory A Storch; Anucha Apisarnthanarak; Robert E Schmidt; Stuart Weiss; Louis B Polish
Journal:  J Neurovirol       Date:  2006-06       Impact factor: 2.643

5.  Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women.

Authors:  Elizabeth A Stier; Stephen E Goldstone; Mark H Einstein; Naomi Jay; John M Berry; Timothy Wilkin; Jeannette Y Lee; Teresa M Darragh; Maria Da Costa; Lori Panther; David Aboulafia; Joel M Palefsky
Journal:  AIDS       Date:  2013-02-20       Impact factor: 4.177

6.  Fulminant hepatic failure secondary to acyclovir-resistant herpes simplex virus.

Authors:  Lokesh Shahani
Journal:  BMJ Case Rep       Date:  2016-10-17

7.  Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir.

Authors:  Earl R Kern; Deborah J Collins; W Brad Wan; James R Beadle; Karl Y Hostetler; Debra C Quenelle
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

8.  A multicenter phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes.

Authors:  S L Sacks; S D Shafran; F Diaz-Mitoma; S Trottier; R G Sibbald; A Hughes; S Safrin; J Rudy; B McGuire; H S Jaffe
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 9.  [Varicella-zoster virus infections].

Authors:  H M Lilie; S W Wassilew
Journal:  Hautarzt       Date:  2004-09       Impact factor: 0.751

10.  Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.

Authors:  Scott Parker; Jill Schriewer; Christina Oberle; Alice Robertson; Randall Lanier; George Painter; R Mark Buller
Journal:  Antivir Ther       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.